Экологические аспекты чувствительности к антибиотикам анаэробных бактерий

Клиническая Микробиология и Антимикробная Химиотерапия. 2001; 3(1):39-47

​ Качерес М., Норд К., Веинтрауб А.
анаэробы антибиотикотерапия антибиотикорезистентность
Раздел
Антибиотикорезистентность
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2001; 3(1):39-47

Аннотация

В статье представлены основные подходы к антибиотикотерапии анаэробных инфекций, описаны наиболее типичные анаэробные патогены и механизмы их резистентности к антимикробным препаратам. Приведены данные исследований чувствительности к антибиотикам Bacteroides spp., Clostridium spp. и Fusobacterium spp., выделенных у госпитализированных пациентов в Швеции и Никарагуа, получавших антибактериальную терапию, а также у детей в возрасте до 2 лет в Никарагуа, получавших и неполучавших антибиотики. Наименее активными в отношении Bacteroides spp. были бензилпенициллин, цефалотин и пиперациллин, которые несколько превосходили клиндамицин и цефокситин. Обнаружены штаммы Fusobacterium spp., устойчивые к бензилпенициллину. Большинство штаммов Clostridium spp. были чувствительны к тестированным антибиотикам. Единственными анаэробами, устойчивыми к ампициллину и цефокситину, оказались Bacteroides spp., выделенные у детей, получавших антибиотики. Ни у детей, ни у взрослых не обнаружено штаммов, устойчивых к имипенему, метронидазолу и хлорамфениколу. Резистентность анаэробов, выделенных у 219 пациентов в Никарагуа, определялась к наиболее часто используемым в этой стране антибиотикам. Так, представители группы B.fragilis часто проявляли резистентность к ампициллину (56%), цефокситину (28%) и клиндамицину (25%). Обнаружены штаммы Fusobacterium spp., устойчивые к ампициллину (44%) и цефокситину (12%).

  • 1. Finegold S.M. Anaerobic infections in humans: An overview. Anaerobe 1995;1:3-9.
  • 2. Nord C.E. Treatment of intraabdominal infections. World wide clinical trials. Infect Dis Clin Pract 1995; 4:S17-25.
  • 3. Brismar B., Nord C.E. Monobactams and carbapenems for treatment of intraabdominal infections. Infection 1999;27:136-47.
  • 4. Olsen I., Solberg C.O., Finegold S.M. A primer on anaerobic bacteria and anaerobic infections for the uninitiated. Infection 1999;27:159-65.
  • 5. Nord C.E. Use of newer quinolones for the treatment of intraabdominal infections: Focus on clinafloxacin. Infection 1999;27:166-72.
  • 6. Gorbach S.L. Antibiotic treatment of anaerobic infections. Clin Infect Dis 1994;18:305-10.
  • 7. Rasmussen B.A., Bush K., Tally F.P. Antimicrobial resistance in anaerobes. J Infect Dis 1997;24:110-20.
  • 8. Hedberg M., Nord C.E. Beta-lactam resistance in anaerobic bacteria. J Chemother 1996;8:3-16.
  • 9. Garcia-Rodriguez J.A., Garcia-Sanchez J.E., Munoz-Bellido J.L. Antimicrobial resistance in anaerobic bacteria: Current situation. Anaerobe 1995;1:69-80.
  • 10. Lubbe M.M., Botha P.L., Chalkley L.Y. Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa. Eur J Clin Microbiol Infect Dis 1999;18:46-54.
  • 11. Wexler H.M., Molitoris E., Mollitoris D., Finegold S.M. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob Agents Chemother 1998;42:984-6.
  • 12. Zwolska Z., Jezierska-Anczukow A., Filczak K., et al. A Polish multicenter survey of Antimicrobial susceptibility and prevalence of b-lactamase productions among bacterial pathogens isolated from hospitalized and ambulatory patients. Pol Merkuriusz Lek 1998;4:241-6.
  • 13. Doern G.V., Johns R.N., Pfaller M.A., Kugler K.C., Beach M.L. The SENTRY Study Group (North America). Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 1999;34:65-72.
  • 14. Wise R. A review of the mechanisms of action and resistance of antimicrobial agents. Can resp J 1999;6:20A-2A.
  • 15. Sloan J., Murry L.M., Luras D., Levy S.B., Rood J.L. The Clostridium perfringens TetP determinant comprises two overlapping genes: tet(P), which mediates active tetracycline efflux, and tetB(P), which is related to the ribosomal protection family of tetracycline-resistance determinants. Mol Microbiol 1994;11:403-15.
  • 16. Anderson J.D., Sykes R.B. Characterization of a b-lactamase obtained from a strain of Bacteroides fragilis resistant to beta-lactam antibiotics. J Med Microbiol 1973;6:201-6.
  • 17. Olsson B., Nord C.E., Wadstrom T. Formation of b-lactamase in Bacteroides fragilis: Cell bound and extracellular activity. Antimicrob Agents Chemother 1976;9:727-35.
  • 18. Sato K., Inoue M., Mitsuhashi S. Activity of b-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins. Antimicrob Agents Chemother 1980; 17:736-7.
  • 19. Brook I., Calhoun L., Yocum P. b-Lactamase-producing isolates of Bacteroides species from children. Antimicrob Agents Chemother 1980;18:164-6.
  • 20. Heimdahl A., Von Konow L., Nord C.E. b-Lactamase producing Bacteroides species in the oral cavity in relation to penicillin therapy. J Antimicrob Chemother 1981;8:225-9.
  • 21. Ednie L.M., Jacobs M.R., Appelbaum P.C. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother 1998;42:2459-62.
  • 22. Hoellman D.B., Spangler S.K., Jacobs M.R., Appelbaum P.C. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds. Antimicrob Agents Chemother 1998;42:495-501.
  • 23. Nyfors S., Kononen E., Takala A., Jousimies-Somer H. b-Lactamse production by oral anaerobic Gram-negative species in infants in relation to previous antimicrobial therapy. Antimicrob Agents Chemother 1999;43:1591-4.
  • 24. Nord C.E. Mechanisms of beta-lactame resistance in anaerobic bacteria. Rev Infect Dis 1986;8:543-7.
  • 25. Kesado T., Lindqvist L., Hedberg M., Tuner K., Nord C.E. Purification and characterization of a new b-lactamase from Clostridium butyricum. Antimicrob Agents Chemother 1989;33:1302-7.
  • 26. Hedberg M., Lindqvist L., Tuner K., Nord C.E. Effect of clavulanic acid, sulbactam and tazobactam on three different b-lactamase from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum. J Antimicrob Chemother 1992;30:17-25.
  • 27. Nord C.E., Hedberg M. Resistance to beta-lactam antibiotics in anaerobic bacteria. Rev Infect Dis 1990;12:231-3.
  • 28. Sato K., Matsuura Y., Inoue M., Mitsuhashi S. Properties of a new penicillinase type produced by Bacteroides fragilis. Antimicrob Agents Chemother 1982;22:579-84.
  • 29. Lacroix J.M., Lamothe F., Malaquin F. Role of Bacteroides bivius b-lactamase in beta-lactam susceptibility. Antimicrob Agents Chemother 1984;26:694-8.
  • 30. Hedberg M., Edlund C., Lindqvist L., Rylander M., Nord C.E. Purification and characterization of a new imipenem hydrolising metallo- b-lacatamase from Bacteroides fragilis. J Antimicrob Chemother 1992;29:105-13.
  • 31. Tuner K., Lindqvist L., Nord C.E. Purification and properties of a novel b-lactamase from Fusobacterium nucleatum. Antimicrob Agents Chemother 1985;27:943-7.
  • 32. Sato K., Matsuura Y., Miyata M., Inoue M., Mitsuhashi S. Characterization of cephalosporinases from Bacteroides fragilis, Bacteroides thetaiotaomicron and Bacteroides vulgatus. J Antibiot 1983;36:76-85.
  • 33. Brook I. Anaerobic infections. Med Microbiol 1999; 10:137-53.
  • 34. Stratton C.W. Mechanisms of action for antimicrobial agents: General principles and mechanisms for selected classes of antibiotics. In: Lorian V., ed. Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins; 1996. p. 579-603.
  • 35. Freeman C.D., Klutman N.E., Lamp K.C. Metronidazole: A therapeutic review and update. Drugs 1997;54:679-780.
  • 36. Caceres M., Hedberg M., Lindqvist L., Nord C.E. Purification and characterization of a beta-lactamase from Bacteroides distasonis. J Chemother 1991;3 (Suppl): 131-4.
  • 37. Caceres M., Carera E., Palmgren A.-C., Nord C.E. Antimicrobial susceptibility of anaerobic bacteria from the intestinal microflora of healthy children and antimicrobial-treated children in Nicaragua. Span J Chemother 1998;3:221-8.
  • 38. Caceres M., Carera E., Palma A., Berrios G., Weintraub A., Nord C.E. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from mixed infections in Nicaragua. Span J Chemother 1999;12:332-9.
  • 39. Caceres M., Zhang G., Weintraub A., Nord C.E. Prevalence and antimicrobial susceptibility of enterotoxigenic Bacteroides fragilis in children with diarrhea in Nicaragua. Anaerobe 2000;6:143-8.
  • 40. Edlund C., Nord C.E. Ecological impact of antimicrobial agents on human intestinal microflora. Alpe Adria Microbiol J 1993;3:137-64.
  • 41. Okeke I.N., Lamikanra A., Edelman R. Socioeconomic and behavioral factors seeding to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999;5:18-27.
  • 42. Stark C., Edlund C., Nord C.E. Ecological balance and disturbance in the oropharyngeal and gastrointestinal microflora. Span J Chemother 1996;4:250-9.
  • 43. Durmaz B., Durmas R., Tastekin N. Evaluation of culture results of specimens from patients with suspected anaerobic infection. Microbiologica 1999;22:155-9.
  • 44. Bush K. Characterization of b-lactamases. Antimicrob Agents Chemother 1989;33:259-63.
  • 45. Medeiros A.A. Evolution and dissemination of b-lactamases accelerated by generations of b-lactam antibiotics. Clin Infect Dis 1997;24:S10-45.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились